Nuvation Bio is trading 6.1% down at $5.70, with the decline appearing consistent with broader risk-off trading and no new company-specific catalyst identified for September 14, 2026.
- Recent investor-conference commentary and clinical updates occurred earlier, including September 9–10.
- S&P 500 futures fell 0.7% and Nasdaq futures declined 1.7%; oil climbed amid Middle East tensions.
- Rate-hike concerns pressured equities.